---
title: "FDA advisory committee ties draw scrutiny, GLP-1 trial to test Wegovy for addiction and social out"
id: "stat-news-0-stat-fda-adcomm-members-ties-to-industry-under-scrutiny"
canonical_url: "https://medichelpline.com/clinical-feed/stat-news-0-stat-fda-adcomm-members-ties-to-industry-under-scrutiny"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "STAT News"
source_url: "https://www.statnews.com/2026/10/14/biotech-news-fda-adcomm-member-ties-to-industry-under-scrutiny/?utm_campaign=rss"
published_at: "2026-10-14T14:12:14.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# FDA advisory committee ties draw scrutiny, GLP-1 trial to test Wegovy for addiction and social out
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/stat-news-0-stat-fda-adcomm-members-ties-to-industry-under-scrutiny
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** STAT News
- **Source URL:** [Original Journal Publication](https://www.statnews.com/2026/10/14/biotech-news-fda-adcomm-member-ties-to-industry-under-scrutiny/?utm_campaign=rss)
- **Published At:** 2026-10-14T14:12:14.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Investigators reported growing scrutiny over ties between FDA advisory committee members and industry; the source headline flagged the issue but provided no supporting details in the body. - The Center for Addiction Science, Policy and Research (CASPR) and the Allegheny County Department of Human Services plan a randomized trial starting in early 2027, according to a press release the story cited. - The planned study will enroll up to 1,200 adults with **alcohol use disorder** (AUD), **opioid use disorder** (OUD), or both, specifically recruiting people at high risk of criminal-justice involvement. - The trial will randomize about half the participants to receive Novo Nordisk’s **Wegovy**, the article stated; investigators reported that the study will examine criminal-justice outcomes and broader measures such as employment, health, and housing. - The source did not report key methodological details: dosing regimen, treatment duration, primary and secondary endpoints, follow-up length, or prespecified statistical plans were not provided in the article. - The article also noted, without detail, a settlement between **Liquidia** and **United Therapeutics** resolving patent litigation over a pulmonary arterial hypertension treatment; no trial or clinical data were presented. - The source linked to separate coverage of related issues, including adcomm membership ties and other biotech headlines, but did not provide additional quantitative results or regulatory timelines for the GLP-1 trial.
## Clinical Analysis & Structured Key Points
FDA adcomms, GLP-1s, Martin Shkreli: Readout Newsletter Skip to Main Content STAT Plus Newsletter The Readout FDA adcomm members’ ties to industry under scrutiny The FTC going after Martin Shkreli again, a study on GLP-1s and social outcomes, and more biotech news Manage alerts for this article Save this story for later Share this article Adobe By Elaine Chen Oct. 14, 2026 National Biotech Reporter Elaine Chen [email protected] Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter , and co-hosts STAT’s weekly biotech podcast, The Readout Loud . You can reach Elaine on Signal at elaineywchen.70. Good morning. Yesterday, we got the devastating news that STAT’s infectious disease correspondent, Helen Branswell, passed away. She was a reporter I always looked up to and was also an incredibly generous colleague. Please take the time to read this tribute to her. The need-to-know this morning Liquidia and United Therapeutics reached a settlement agreement that resolves their ongoing patent litigation over Liquidia’s treatment for pulmonary arterial hypertension. New trial to test effect of GLP-1s on social outcomes Researchers in Pittsburgh are launching a novel type of GLP-1 trial — testing not only if the drug will help people with addiction, but also if it will help reduce recidivism while improving other employment, health, and housing outcomes. Advertisement The Center for Addiction Science, Policy and Research (CASPR), a non-profit organizing the effort, and the Allegheny County Department of Human Services are planning to launch the trial in early 2027. They will enroll up to 1,200 adults with alcohol use disorder, opioid use disorder, or both, who are also at high risk of criminal-justice involvement. Half will be randomly assigned to take Novo Nordisk’s Wegovy, according to a press release issued yesterday. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Individual plans Group plans Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology , Clinical trials , drug development , Drug prices , Mental Health , Obesity , research Submit a correction request Reprints Elaine Chen National Biotech Reporter Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter , and co-hosts STAT’s weekly biotech podcast, The Readout Loud . You can reach Elaine on Signal at elaineywchen.70. Newsletter Your morning rundown of the science, politics, and money driving biotech today Please enter a valid email address. Sign Up Your data will be processed in accordance with our Privacy Policy and Terms of Service . You may opt out of receiving STAT communications at any time. Recommended Biotech Biotech October 13, 2026 STAT Plus: Concerns grow on safety issues tied to Neurocrine Biosciences rare disease drug The Readout The Readout October 9, 2026 STAT Plus: Life Biosciences share glaucoma study updates for its cellular reprogramming drug Advertisement The Readout The Readout October 8, 2026 STAT Plus: Roche goes beyond licensing in deal with Chinese biotech Biotech Biotech October 8, 2026 STAT Plus: Argenx sees unusual setback with failure of late-stage study of drug for autoimmune disease Pharma Pharma October 8, 2026 STAT Plus: Roche inks drug discovery deal with Chinese biotech, focused on molecular glue medicines Subscriber Picks
## Related Clinical Research

- [Remote robot-assisted sleeve gastrectomy with anti-reflux surgery: safety and early outcomes](https://medichelpline.com/clinical-feed/pubmed-42927966.md) (DOI: 10.3760/cma.j.cn441530-20260622-00247)
- [Comorbid Cardiovascular–Liver Disease Disparities: MASLD, CVD Risk, and Equity-Focused Care](https://medichelpline.com/clinical-feed/pubmed-42827168.md) (DOI: 10.1007/s11886-026-02426-9)
- [Community pharmacists’ roles and barriers in health promotion and disease prevention in Jordan: CO](https://medichelpline.com/clinical-feed/plos-one-8-factors-influencing-community-pharmacists-provision-of-health-promotion-and.md)
- [CKM Burden Predicts Echocardiographic Recovery and Cardiovascular Events in Hypertension](https://medichelpline.com/clinical-feed/medrxiv-6-impact-of-cardiovascular-kidney-metabolic-burden-on-echocardiographic.md)
- [Phenome-Wide Clinical Atlas Linking Obstructive Sleep Apnea to Multidomain EHR Signals](https://medichelpline.com/clinical-feed/medrxiv-18-a-clinical-atlas-for-phenome-wide-association-study-of-obstructive-sleep-apnea.md)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.